| pioglitazone / Generic mfg. |
ACTRN12605000174684: Anti-inflammatory effects of pioglitazone in acute stroke - a double-blind placebo controlled trial |
|
|
| Not yet recruiting | 4 | 45 | | | Dr R W Simpson | Acute stroke | | | | |
ACTRN12611000351910: The effect of Pioglitazone on Cardiovascular and Psychiatric status of non-Diabetic Metabolic Syndrome Patients |
|
|
| Active, not recruiting | 4 | 140 | | | Osvah Pharmaceutical Company, Isfahan Cardiovascular Research Center | Metabolic Syndrome, Mental health screening indicators | | | | |
ChiCTR-TRC-08000111: A multicenter study of effects of early prevention on adult metabolic syndrome in Beijing region |
|
|
| Recruiting | 4 | 600 | | Intervention on life habit + pioglitazone ;Intervention on life habit + dimethyldiguanide ;Intervention on life habit + placebo: 100 with dimethyldiguanide placebo tablet and 100 with pioglitazone placebo tablet | China-Japan Friendship Hospital; Beijing Municipal Health Bureau., Capital Medical Developmental Fund | Metablic Syndrome | | | | |
ChiCTR-TRC-08000099: Multicenter Research of Early Intervention for Adult Metabolic Syndrome in Beijing Region |
|
|
| Completed | 4 | 600 | | Life style intervention + Metformin ;Life style intervention + placebo: Metformin placebo tablets are given in 100 patients, and Pioglitazone placebo tablets are given in another 100 patients ;Life style intervention + placebo | China-Japan Friendship Hospital of Ministry of Health of the People's Republic of China; Beijing Municipal Bureau of Public Health. B Zhonghuan Square, # 70, Zaolinqian Street, Xuanwu District, Beijing, Capital medical development fundation | Metabolic syndrome | | | | |
ChiCTR-TRC-10000879: Comparison of glycaemic control and beta-cell function among newly diagnosed type 2 diabetic patients treated with exenatide, insulin or rosiglitazone: a multicentre randomized parallel-group trial |
|
|
| Completed | 4 | 414 | | Exenatide injection (Byetta) ;Premixed insulin analog (Humalog Mix 25) ;Pioglitazone (Ruitong) | The Third Affiliated Hospital of Sun Yat-Sen University; Peking University People's Hospital, Eli Lilly, 5010 Program of Sun Yat-Sen University, Ministry of Health | Type 2 diabetes | | | | |
| Completed | 4 | 2000 | | Intensive lifestyle intervention plus placebo ;Conventional lifestyle intervention plus pioglitazone ;Intensive lifestyle intervention plus pioglitazone ;Conventional lifestyle intervention plus placebo | People's Hospital, Peking University; Beijing Municipal Science & Technology Committee, Beijing Municipal Science & Technology Committee | Diabetes | | | | |
ChiCTR-OPC-17011571: Effects of pioglitazone on insulin sensitivity and function of pancreatic α and β cells in type 2 diabetic patients with different body weight |
|
|
| Completed | 4 | 68 | | Pioglitazone ;Pioglitazone | Fuwai Hospital, Chinese Academy of Medical Sciences; Level of the institution：, Tekada, Pfizer | Type 2 Diabetes | | | | |
2004-003822-80: Modulation of Sympathetic Nerve Activity By Pioglitazone In Type 2 Diabetes Mellitus |
|
|
| Ongoing | 4 | 16 | Europe | Actos (Pioglitazone), Actos (Pioglitazone) | The Leeds Teaching Hospitals NHS Trust | Type 2 diabetes mellitus | | | | |
2006-002084-49: Vascular function in impaired glucose tolerance - effect of pioglitazone |
|
|
| Ongoing | 4 | 104 | Europe | Pioglitazone, Actos, Actos | Belfast City Hospital Trust | Impaired glucose tolerance | | | | |
2006-001982-41: An evaluation of the safety and effectiveness of combination therapy using the thiazolidinedione pioglitazone alongside insulin in type 2 diabetes mellitus. |
|
|
| Ongoing | 4 | 40 | Europe | Actos Tablets, Actos, Actos | Bradford Teaching Hospitals NHS Foundation Trust | Type 2 Diabetes Mellitus | | | | |
2007-003152-10: Influence du traitement par glitazones sur les Phospholipases A2 et sur l\'effet des Lipoprotéines de haute densité (HDL) sur la réactivité artérielle, au cours du diabète de type 2 |
|
|
| Ongoing | 4 | 60 | Europe | PIOGLITAZONE, ROSIGLITAZONE, PIOGLITAZONE, ROSIGLITAZONE | CHU DIJON | Diabète de type 2 | | | | |
2006-004296-35: An investigation into the modulation of obesity associated monocyte/macrophage function, vascular inflammation and insulin resistance by PPAR agonist treatment |
|
|
| Ongoing | 4 | 80 | Europe | Actos, Supralip 160, Actos, Supralip 160 | The Royal Group of Hospitals, Belfast Health and Social Care Trust, Queen\'s University Belfast | The proposed study will investigate early indicators of cardiovascular disease and diabetes in healthy, obese men without a family history of diabetes and whether these are changed by treatment with the common PPAR agonists fenofibrate andpioglitazone. | | | | |
2006-007027-14: Influence du traitement par Pioglitazone sur l\'Ostéoprotégérine dans le diabète de tye II |
|
|
| Ongoing | 4 | 104 | Europe | Actos 30 mg, Actos 45 mg, Actos 30 mg, Actos 45 mg | INSERM | Diabète de type II | | | | |
2007-007884-26: Pioglitatsonin käyttö potilailla, joilla krooninen rasvamaksasairaus ja tuore tyypin 2 diabetes |
|
|
| Ongoing | 4 | 10 | Europe | Actos, Actos | HUS, HYKS, Diabetesklinikka | K76.9 RasvamaksaE11 Tyypin 2 diabetes | | | | |
2007-007075-16: The effect of peroxisome proliferator activator receptor γ agonist pre-treatment on pegylated interferon-α2a and ribavirin efficacy in hepatitis C patients, previously resistant to treatment with pegylated interferon and ribavirin - a randomized-controlled trial - |
|
|
| Ongoing | 4 | 50 | Europe | Copegus, Actos, Pegasys, Actos, Pegasys | VU university medical center | Chronic hepatitis C infection | | | | |
2009-011106-42: Aditive effects of omega-3 polyunsaturated fatty acids and pioglitazone in the treatment of type 2 diabetes mellitus |
|
|
| Ongoing | 4 | 60 | Europe | ACTOS 15 MG POR TBL NOB 28X15MG, Epax 1050TG, ACTOS 15 MG POR TBL NOB 28X15MG, Epax 1050TG | Institute for Clinical and Experimental Medicine | The project deals with hummoral and metabolic aspects of insulin resistance (IR), which is assumed to be the basic metabolic disorder which leads to the development of type 2 diabetes mellitus (T2D) and metabolic syndrome. Study population will be patients with T2D treated by metformin. | | | | |
| Ongoing | 4 | 100 | Europe | Actos, Actos | Nottingham University | Asthma | | | | |
2009-016678-34: Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon |
|
|
| Ongoing | 4 | 22 | Europe | Actos, ViraferonPeg, Actos, ViraferonPeg, Actos, ViraferonPeg | Imperial College London | HCV infected patient who do not response to Pegylated Interferon. This study is trying to explore the relationship between insulin resistance and Interferon Resistance and the possible rule of Pioglitazone treatment to improve Interferon sensetivity. | | | | |
2015-002104-91: A Randomised Controlled Trial for People with Established Type 2 Diabetes during Ramadan: Canagliflozin (Invokana™) vs. standard dual therapy regimen: The ‘Can Do Ramadan’ Study. The ‘Can Do Ramadan’ Trial |
|
|
| Ongoing | 4 | 116 | Europe | Canagliflozin, Gliclazide, Glimepiride, Glibenclamide, Glipizide, Repaglinide, Pioglitazone, Film-coated tablet, Tablet, Invokana, The sulphonylurea - Gliclazide, Repaglinide, Prandin, Actos | University of Leicester | Type 2 Diabetes Mellitus, Diabetes, Body processes [G] - Metabolic Phenomena [G03] | | | | |
ChiCTR-OPC-17011930: Clinical research of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets in the treatment of polycystic ovary syndrome |
|
|
| Completed | 4 | 30 | | Take Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets | Shanghai Changhai Hospital; Shanghai Changhai Hospital, Self financing | polycystic ovary syndrome | | | | |
NCT03646292: Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver |
|
|
| Recruiting | 4 | 60 | RoW | Pioglitazone, Empagliflozin, Combination of pioglitazone and empagliflozin | Yonsei University | NAFLD - Nonalcoholic Fatty Liver Disease, Type2 Diabetes | 02/21 | 02/21 | | |
ChiCTR1900028606: A randomized controlled trial for pioglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in patients with type 2 diabetes inadequately controlled with metformin |
|
|
| Not yet recruiting | 4 | 304 | | Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets ;Metformin Hydrochloride Tablets | Beijing Hospital; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Diabetes | | | | |
| Recruiting | 4 | 1506 | RoW | Pioglitazone 45 mg | Dasman Diabetes Institute, Ministry of Health, Kuwait, Texas Diabetes Institute, Kuwait University | Covid19, Type 2 Diabetes | 06/21 | 06/21 | | |
| Completed | 4 | 8 | Europe | Pioglitazone 30 mg, standard of care | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | Type 2 Diabetes | 11/21 | 01/22 | | |
NCT02315287: Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management |
|
|
| Recruiting | 4 | 190 | RoW | Pioglitazone, Actos, Lobeglitazone, Duvie | Seoul National University Bundang Hospital | Type 2 Diabetes | 12/21 | 12/21 | | |
NCT04584242: Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes |
|
|
| Recruiting | 4 | 40 | RoW | gluconon tab 15mg, suganon tab 5mg | Yonsei University | Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes | 05/22 | 05/22 | | |
| Completed | 4 | 57 | Europe | Liraglutide, Pioglitazone | University of Leeds | Diabetes Mellitus, Type 2 | 10/22 | 10/22 | | |
| Active, not recruiting | 4 | 26 | Europe | Acetazolamide, Diamox, ATC code: S01EC01, Placebo | University Hospital, Antwerp | Obstructive Sleep Apnea | 04/23 | 08/24 | | |
NCT05519813: Effects of Pioglitazone Combined With Metformin on Gonadal and Metabolic Profiles in Chinese Nonobese PCOS Patients. |
|
|
| Active, not recruiting | 4 | 60 | RoW | Metformin, Pioglitazone Hydrochloride And Metformin Hydrochloride Tablets | Bing He | Polycystic Ovary Syndrome | 01/23 | 03/23 | | |
NCT05473806: Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes |
|
|
| Active, not recruiting | 4 | 28 | RoW | Pioglitazone 15 Mg Oral Tablet, Gluconon tablet 15mg, Evogliptin 5mg, SUGANON tablet 5mg | Seung Up Kim | Hepatitis B, Chronic, Fibrosis, Liver, Diabetes Mellitus, Type 2 | 01/23 | 02/23 | | |
NCT06164665: Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude |
|
|
| Completed | 4 | 9 | US | Pioglitazone 15mg, Actos, Placebo | United States Army Research Institute of Environmental Medicine | High Altitude | 07/23 | 07/23 | | |
NCT04976283: Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver |
|
|
| Recruiting | 4 | 123 | RoW | Pioglitazone, Zolid, Empagliflozin, Diampa, Pioglitazone + Empagliflozin, Zolid + Diampa | Getz Pharma | Diabetes Mellitus, Type 2, NASH - Nonalcoholic Steatohepatitis, NAFLD | 05/23 | 11/23 | | |
| Recruiting | 4 | 20 | RoW | Pioglitazone 45 mg, pioglitazone hydrochloride | University of Campinas, Brazil | Myocardial Reperfusion Injury | 06/24 | 12/24 | | |
| Recruiting | 4 | 120 | US, RoW | Pioglitazone 45 mg, Placebo | The University of Texas Health Science Center at San Antonio | Type 1 Diabetes Mellitus | 12/24 | 01/25 | | |
NCT04370093: Pathogenesis of Uric Acid Nephrolithiasis: Role of Pioglitazone/Weight Loss |
|
|
| Recruiting | 4 | 54 | US | Pioglitazone 45 mg, Weight Loss, Pioglitazone + Weight Loss | University of Texas Southwestern Medical Center | Nephrolithiasis, Uric Acid | 06/25 | 07/25 | | |
EPIDOTE, NCT03499704: A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by DPP-4 Inhibitor and Metformin Therapy |
|
|
| Active, not recruiting | 4 | 133 | RoW | Pioglitazone + Alogliptin, SYR-322-4833, Alogliptin, Metformin, Dapagliflozin | Celltrion Pharm, Inc. | Diabetes Mellitus, Type 2 | 01/24 | 06/24 | | |
NCT06243536: The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients |
|
|
| Not yet recruiting | 4 | 60 | RoW | Semaglutide, standard of care, Metformin, Sulfonylureas, Sodium-glucose cotransporter-2 inhibitors, pioglitazone | University Hospital "Sestre Milosrdnice", University of Zagreb School of Medicine | Type 2 Diabetes, Overweight, Disordered Eating Behaviors | 12/24 | 12/24 | | |
NCT06399835: Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis |
|
|
| Recruiting | 4 | 120 | RoW | Enavogliflozin, Envlo Tab., Pioglitazone, Actos Tab. | Seoul National University Bundang Hospital, Daewoong Pharmaceutical Co. LTD. | Type 2 Diabetes | 06/26 | 12/26 | | |
NCT05813249: Semaglutide in Nonalcoholic Fatty Liver Disease |
|
|
| Completed | 4 | 180 | RoW | Rybelsus Oral Product, Ozempic Injectable Product, Wegovy, Tocopherol and/or Actos | Zagazig University | Non-alcoholic Fatty Liver Disease | 02/24 | 04/24 | | |
NCT03471117: Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients |
|
|
| Recruiting | 4 | 28 | US | Pioglitazone, Placebo | The University of Texas at Arlington, University of Texas, Southwestern Medical Center at Dallas | Chronic Kidney Diseases | 04/25 | 04/25 | | |
NCT05942963: Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD |
|
|
| Not yet recruiting | 4 | 240 | RoW | Empagliflozin 10 MG, Pioglitazone 15mg, Metformin | Jinnah Postgraduate Medical Centre | Non-Alcoholic Fatty Liver Disease, Type2diabetes | 04/24 | 04/24 | | |
ChiCTR2200062954: Pioglitazone in spontaneous subarachnoid hemorrhage: A multicentre, double-blind, randomised trial |
|
|
| Not yet recruiting | 4 | 400 | | Pioglitazone treatment ;Placebo treatment | 904th Hospital of Joint Logistic Support Force; 904th Hospital of Joint Logistic Support Force, Natural Science Foundation of Jiangsu Province; Wuxi key demonstration project | Spontaneous subarachnoid hemorrhage | | | | |
NCT05305287: Quantifying Hepatic Mitochondrial Fluxes in Humans |
|
|
| Recruiting | 4 | 60 | US | Pioglitazone, Actos, Placebo | The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders | 03/27 | 03/27 | | |
| Recruiting | 4 | 78 | US | Pioglitazone, Actos, Placebo, Placebo tablet | The University of Texas Health Science Center at San Antonio | Type 2 Diabetes Mellitus in Obese, Heart Failure With Preserved Ejection Fraction | 04/28 | 01/29 | | |
| Ongoing | 3 | 60 | Europe | Pioglitazona, A10BG03, Tablet | Hospital Universitario Araba (Sede Santiago), No | Bipolar disorder Trastorno bipolar, Bipolar disorder Trastorno bipolar, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2004-002466-38: A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11%.52 week extension to a multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11%. |
|
|
| Ongoing | 3 | 20 | Europe | not established, Actos, LAF 237, 18/270/01-C, not extablished, Actos, not extablished, Actos | Novartis Pharma AG | Diabetes mellitus | | | | |
2005-001218-42: Clinical role of PPAR gamma activator (pioglitazone) in reducing the gastric phlogosis in patiens with istological gastritis. |
|
|
| Ongoing | 3 | 80 | Europe | ACTOS*28CPR 15MG, ACTOS*28CPR 15MG | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | Treatment of patients with gastric phlogosis (infected by Helicobacter pylori) | | | | |
2012-004100-35: clinical trial in adolescents with ovarian hyperandrogenism and hyperinsulinemia: Effects on ovulatory function, parameters of chronic inflammation, on cardiovascular risk factors and on risk factors for the development of type 2 diabetes Ensayo clínico en adolescentes con hiperandrogenismo ovárico e hiperinsulinismo: efectos sobre la función ovulatoria, parámetros de inflamación crónica, marcadores de riesgo cardiovascular y de desarrollo de diabetes tipo 2. |
|
|
| Ongoing | 3 | 40 | Europe | Metformina, espironolactona, Clorhidrato de pioglitazona, LOETTE DIARIO, Metformina Sandoz, Aldactone Pfizer, Actos®, LOETTE DIARIO, Metformina Sandoz, Aldactone Pfizer, Actos®, LOETTE DIARIO | Fundació per la Recerca i la Docència Sant Joan de Déu, Ministerio de Sanidad y Política Social | Ovarian hyperandrogenism hiperandrogenismo ovárico | | | | |
2015-005092-24: Clinical trial in adolescents with ovarian hyperandrogenism and hyperinsulinemia: Effects on ovulatory function, parameters of chronic inflammation, treatment markers of pronostic and effectiveness and the development of type 2 diabetes. Ensayo clínico en adolescentes con hiperandrogenismo ovárico e hiperinsulinismo: efectos sobre la función ovulatoria, parámetros de inflamación crónica, marcadores de evolución y efectividad del tratamiento y de desarrollo de diabetes tipo 2. |
|
|
| Ongoing | 3 | 40 | Europe | Metformina Sandoz, Aldactone, Pioglitazona Cinfa, LOETTE DIARIO, Metformina Sandoz, Aldactone, Pioglitazona Cinfa, LOETTE DIARIO | FUNDACIÓ SANT JOAN DE DÉU, Ministerio de Sanidad y Política Social | ovarian hyperandrogenism with hyperinsulinaemia hiperandrogenismo ovárico con hiperinsulinismo | | | | |
NCT04885712: A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin |
|
|
| Completed | 3 | 378 | RoW | Metformin≥1000mg, BR3003D, Pioglitazone 15mg, BR3003A-1, Pioglitazone 30 mg, BR3003B-1, Pioglitazone 15mg Placebo, BR3003A-2, Pioglitazone 30mg Placebo, BR3003B-2, Dapagliflozin 10mg, BR3003C | Boryung Pharmaceutical Co., Ltd | Type2 Diabetes | 09/22 | 03/23 | | |
| Withdrawn | 3 | 40 | US | Pioglitazone 30 mg, Actos, Placebo | State University of New York at Buffalo, National Center for Advancing Translational Sciences (NCATS) | Prostate Cancer, Insulin Resistance, Diabetes Mellitus, Type 2, Androgen Deficiency | 03/23 | 03/23 | | |
NCT05605158: Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis |
|
|
| Not yet recruiting | 3 | 56 | RoW | Pioglitazone 30mg, Empagliflozin 10 MG | Tanta University | Non Alcoholic Steatohepatitis | 05/23 | 11/24 | | |
PIEMONTE, NCT05028140: Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 480 | NA | PIEMONTE, PIEMONTE PLACEBO, EMPAGLIFLOZIN, PLACEBO EMPAGLIFLOZIN, PIOGLITAZONE, PLACEBO PIOGLITAZONE | EMS | Type II Diabetes | 03/26 | 09/26 | | |
RENATO, NCT05946564: A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - Trial |
|
|
| Not yet recruiting | 3 | 126 | NA | Pioglitazone (ACTOS®), Placebo of Pioglitazone | Assistance Publique - Hôpitaux de Paris, Ministry of Health, France | ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis, Crescentic Glomerulonephritis | 12/25 | 06/27 | | |
2008-005546-23: Treating Insulin Resistance in patient after Stroke for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attack |
|
|
| Ongoing | 2/3 | 500 | Europe | Pioglitazone (Actos), AD-4833, Actos, Actos | Yale University School of Medicine, YALE UNIVERSITY, Yale University School of Medicine, | Insulin resistance in patients who have had a stroke or transient ischaemic attack | | | | |
2006-001398-44: The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer |
|
|
| Ongoing | 2 | 80 | Europe | Lipantil Micro, ROCALTROL, Pioglitazone, LIPANTIL, ROCALTROL, LIPANTIL, ROCALTROL | Barts and The London NHS Trust | The use of Peroxisome Proliferator Activator Receptor Agonists in the management of Androgen Independent Prostate Cancer. Open-labeled, non-randomised clinical trial in patients with androgen independent prostate cancer | | | | |
2009-011675-79: A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS®) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC®) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR MOLECULAR RESPONSE (MMR). |
|
|
| Ongoing | 2 | 50 | Europe | PIOGLITAZONE HYDROCHLORIDE, ACTOS 15 mg, ACTOS 15 mg | CH-Versailles | chronic phase chronic myelogenous leukaemia (CP-CML) patients in major molecular response. | | | | |
2009-012226-37: Ensayo clínico piloto de tratamiento con Pioglitazona+Flutamida+Metformina a Dosis Bajas versus Etinil-Estradiol + Acetato de Ciproterona como control, en Adolescentes con Hiperandrogenismo Ovárico e Hiperinsulinismo: Efectos sobre Parámetros de Inflamación Crónica, Diabetes Tipo 2 y Riesgo Cardiovacular |
|
|
| Ongoing | 2 | 48 | Europe | DIANE 35, METFORMINA SANDOZ 850 mg comprimidos recubiertos con película, FLUTAMIDA CINFA 250 mg comprimidos, ACTOS 15 mg comprimdos, DIANE 35, METFORMINA SANDOZ 850 mg comprimidos recubiertos con película, FLUTAMIDA CINFA 250 mg comprimidos, ACTOS 15 mg comprimdos | HOSPITAL SANT JOAN DE DÉU | Hiperandrogenismo ovárico asociado a hiperinsulinismo. | | | | |
2018-003817-16: A 52 weeks double blind, randomized and placebo controlled trial evaluating the effect of oral KIN001 150 mg plus pioglitazone 10 mg daily on injection frequency of Standard of Care in patients with diagnosed unilateral wet AMD undergoing a treat and extend regimen Eine 52-wöchige, doppelblinde, randomisierte und placebokontrollierte Studie zur Bewertung der Wirkung der täglichen oralen Gabe von KIN001 150 mg plus Pioglitazon 10 mg auf das Behandlungsintervall in der Standardtherapie bei Patienten mit diagnostizierter einseitiger feuchter altersbedingter Makuladegeneration (AMD) |
|
|
| Not yet recruiting | 2 | 100 | Europe | Pioglitazone, KIN001, Prolonged-release tablet, Film-coated tablet | Kinarus AG, Kinarus AG | wet age-related macular degeneration feuchte altersbedingte Makuladegeneration, wet age-related macular degeneration feuchte altersbedingte Makuladegeneration, Diseases [C] - Eye Diseases [C11] | | | | |
2020-005626-29: A PHASE II CLINICAL STUDY, ON TRABECTEDIN IN COMBINATION WITH PPARg AGONIST PIOGLITAZONE IN PATIENTS WITH ROUND CELL MYXOID LIPOSARCOMAS OR DEDIFFERENTIATED G1 OR G2 LIPOSARCOMAS WITH STABLE DISEASE IN TREATMENT WITH TRABECTEDIN ALONE. STUDIO CLINICO DI FASE II, VOLTO A VALUTARE L'ASSOCIAZIONE DEL FARMACO TRABECTEDINA E DEL FARMACO PIOGLITAZONE PPARPg AGONISTA, IN PAZIENTI CON LIPOSARCOMA DI TIPO MIXOIDE/ A CELLULE ROTONDE O LIPOSARCOMA DEDIFFERENZIATO G1 E G2, CON MALATTIA STABILE E IN TRATTAMENTO CON IL FARMACO TRABECTEDINA. |
|
|
| Not yet recruiting | 2 | 10 | Europe | Pioglitazone, Trabectedina, [Pioglitazone], [Trabectedina], Tablet, Powder for concentrate for solution for infusion, Pioglitazone, Yondelis | IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, AIRC (bandi per la ricerca indipendente) | Patients with myxoid/round cell liposarcoma treated with at least 4 cycle of T alone with a stable disease at the last tumor evaluation Pazienti con diagnosi di liposarcoma mixoide/a cellule rotonde trattati per almeno 4 cicli con trabectedina da sola e con malattia stabile in base all’ultima valutazione di malattia., Patients who have been diagnosed with round cell myxoid liposarcoma and who have been treated with only trabectedin and who according to the latest assessment have stable disease. Pazienti con diagnosi di liposarcoma di tipo mixoide/ a cellule rotonde che sono stati trattati negli ultimi 4 cicli con solo il farmaco trabectedina e con malattia stabile all'ultima valutazione., Diseases [C] - Cancer [C04] | | | | |
2021-001442-35: A PHASE 2 MONOCENTRIC PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PIOGLITAZONE IN SUBJECTS WITH VITILIGO STUDIO PILOTA DI FASE 2 PER LA VALUTAZIONE DELL’EFFICACIA E DEL PROFILO DI SICUREZZA DEL PIOGLITAZONE IN SOGGETTI CON VITILIGINE |
|
|
| Ongoing | 2 | 20 | Europe | Pioglitazone, [PTZ], Tablet | ISTITUTI FISIOTERAPICI OSPITALIERI | NON SEGMENTAL VITILIGO WITH BSA BETWEEN 2% AND 50% AND A NON-SATISFACTORY RESPONSE (LESS THAN 10%) TO A PREVIOUS PHOTOTHERAPY CYCLE VITILIGINE NON SEGMENTALE CON ESTENSIONE (BSA) COMPRESO TRA 2% E 50% E CON UNA SCARSA RISPOSTA (INFERIORE AL 10%) AD UN PRECEDENTE TRATTAMENTO FOTOTERAPICO, DIFFUSE VITILIGO WITH A NON-SATISFACTORY RESPONSE TO PHOTOTHERAPY VITILIGINE DIFFUSA SCARSAMENTE RESPONSIVA ALLA FOTOTERAPIA, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-002367-21: Fettvävens sammansättning och dess koppling till typ 2 diabetes: En studie som jämför behandling med Empagliflozin, Pioglitazon och Semaglutide |
|
|
| Not yet recruiting | 2 | 60 | Europe | Film-coated tablet, Tablet, Jardiance 25 mg filmdragerade tabletter, Actos 15 mg tabletter, Actos 45 mg tabletter, Rybelsus 3 mg tabletter, Rybelsus 7 mg tabletter, Rybelsus 14 mg tabletter | Karolinska Universitetssjukhuset, Vetenskapsrådet, Diabetesfonden, SRP Diabetes | Diabetes typ 2, Diabetes typ 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
2020-005849-16: An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) |
|
|
| Not yet recruiting | 2 | 432 | Europe, RoW | Pioglitazone, KIN001, Prolonged-release tablet, Film-coated tablet | Kinarus AG, Kinarus AG | COVID-19 development in hospitalized patients infected with SARS-CoV-2, Hospitalized patients suffering from COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
DIASA3, NCT04662866: Effects of Glucose Lowering Agents in South Asian Women With Impaired Glucose Tolerance or Impaired Fasting Glucose |
|
|
| Recruiting | 2 | 64 | Europe | Metformin capsule 500 mg, Empagliflozin encapsulated tablet 10 mg, Pioglitazone encapsulated tablet 30 mg, Linagliptin encapsulated tablet 5 mg, biguanide, glitazone, sodium glucose transport inhibitor, dipeptidyl peptidase inhibitor | Oslo University Hospital, The Research Council of Norway, Norwegian Diabetes Association, South-Eastern Norway Regional Health Authority, University of Oslo, University Hospital, Akershus, Vestre Viken Hospital Trust, University of Glasgow | Impaired Glucose Tolerance, Insulin Sensitivity, Glucose Metabolism Disorders | 12/22 | 10/23 | | |
NCT04995978: Insulin Resistance and Androgen Deprivation Therapy |
|
|
| Withdrawn | 2 | 44 | US | Pioglitazone 30 mg, placebo tablet | St. Louis University | Prostate Cancer, Insulin Resistance | 01/23 | 01/23 | | |
NCT05013255: Pioglitazone Therapy Targeting Fatigue in Breast Cancer |
|
|
| Recruiting | 2 | 30 | US | Pioglitazone 15mg, Actos, Pioglitazone 30 mg | West Virginia University | Breast Cancer, Muscle Fatigue | 04/23 | 04/23 | | |
| Recruiting | 2 | 200 | RoW | Metformin plus Pioglitazone plus an SGLT2 inhibitor | Chang Gung Memorial Hospital, National Taiwan University Hospital, Chiayi Christian Hospital, Tainan Sin-lau Hospital | Diabetes Mellitus, Stroke | 07/23 | 01/24 | | |
NCT05254626: Efficacy and Safety of Dapagliflozin in Patients With Non-alcoholic Steatohepatitis |
|
|
| Active, not recruiting | 2 | 100 | RoW | Dapagliflozin 10Mg Tab, Pioglitazone 30 mg | Cairo University | Non-alcoholic Steatohepatitis | 01/24 | 09/24 | | |
EDI-PIO, NCT02852486: Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response |
|
|
| Active, not recruiting | 2 | 31 | RoW | Pioglitazone 30 Mg Oral Tablet, cloridrato de pioglitazona 30mg EMS S/A, Brasil, imatinib discontinuation | University of Campinas, Brazil | Leukemia, Chronic Myeloid | 02/24 | 02/24 | | |
TRABEPIO, NCT04794127: Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone. |
|
|
| Recruiting | 2 | 10 | Europe | Trabectedin, Trabectedine, Pioglitazone Oral Product, Pioglitazone | Mario Negri Institute for Pharmacological Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Humanitas Hospital, Italy | Liposarcoma, Myxoid, Liposarcoma, Dedifferentiated, Liposarcoma, Round Cell | 12/24 | 02/25 | | |
| Not yet recruiting | 2 | 20 | NA | Pioglitazone 30mg, Actos, Placebo, Labs, Diagnostic labs | Emory University, National Heart, Lung, and Blood Institute (NHLBI) | Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases | 08/28 | 08/28 | | |
SPIOMET4HEALTH, NCT05394142 / 2021-003177-58: A Clinical Trial to Evaluate the Efficacy, Tolerability, and Safety of a Fixed Dose Combination of Spironolactone, Pioglitazone & Metformin (SPIOMET) in Polycystic Ovary Syndrome (PCOS) |
|
|
| Recruiting | 2 | 364 | Europe, RoW | Placebo, Pioglitazone, PIO, Spironolactone, S, Metformin, MET | Fundació Sant Joan de Déu | Polycystic Ovary Syndrome (PCOS) | 04/25 | 04/25 | | |
KIN-FAST, NCT05659459: The Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2 |
|
|
| Suspended | 2 | 400 | Europe | KIN001, Combination Pamapimod 75mg with Pioglitazone 5mg, KIN001-Placebo | Kinarus AG | COVID-19 | 05/25 | 10/25 | | |
| Recruiting | 2 | 24 | US | Pioglitazone 45 mg, Placebo | Pennington Biomedical Research Center | Lung Cancer | 06/25 | 06/26 | | |
| Recruiting | 2 | 20 | US | Pioglitazone 15mg | University of Maryland, Baltimore, Nico Corporation | Intracerebral Haemorrhage, Intraventricular | 07/25 | 07/26 | | |
NCT05875675: Effects of Pioglitazone in Calcific Aortic Valve Disease |
|
|
| Not yet recruiting | 2 | 100 | NA | Drug: Pioglitazone Oral Tablet, Placebo | Wuhan Union Hospital, China | Calcification of Aortic Valve, Aortic Valve Stenosis | 07/25 | 07/28 | | |
NCT04843046: Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention |
|
|
| Recruiting | 2 | 60 | US | Cognitive Behavioral Therapy (CBT), CBT, Pioglitazone, Actos, Placebo, Corn Starch | The University of Texas Health Science Center, Houston, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder | 08/25 | 08/25 | | |
NCT04501406: Low-Dose Pioglitazone in Patients With NASH (AIM 2) |
|
|
| Recruiting | 2 | 166 | US | Pioglitazone, Actos, Placebo | University of Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 2 Diabetes Mellitus (T2DM), Nonalcoholic Steatohepatitis | 08/27 | 08/27 | | |
ACTIW, NCT02767063: Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR |
|
|
| Recruiting | 1/2 | 100 | Europe | Pioglitazone, Avelumab | Versailles Hospital | Leukemia, Myeloid, Chronic-Phase | 11/22 | 06/23 | | |
NCT05107765: Effects of Pioglitazone on Stress Reactivity and Alcohol Craving |
|
|
| Recruiting | 1/2 | 60 | US | Pioglitazone, Placebo | The University of Texas Health Science Center, Houston, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 08/24 | 08/24 | | |
NCT03109288: Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) |
|
|
| Recruiting | 1/2 | 250 | US | Pioglitazone, clemastine fumarate, Dantrolene, Pirfenidone | National Institute of Allergy and Infectious Diseases (NIAID) | Multiple Sclerosis | 01/25 | 01/29 | | |
NCT01586078: Pioglitazone Hydrochloride in Preventing Radiation-Induced Cognitive Dysfunction in Patients With Brain Tumors |
|
|
| Recruiting | 1 | 100 | US | pioglitazone hydrochloride, Actos, pioglitazone, laboratory biomarker analysis, external beam radiation therapy, EBRT, 3-dimensional conformal radiation therapy, 3D-CRT, conformal radiation therapy, intensity-modulated radiation therapy, IMRT, management of therapy complications, complications of therapy, management of | Comprehensive Cancer Center of Wake Forest University, National Cancer Institute (NCI) | Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Meningioma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Choroid Plexus Tumor, Adult Craniopharyngioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Medulloblastoma, Adult Meningeal Hemangiopericytoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Papillary Meningioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Pineoblastoma, Adult Pineocytoma, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma, Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Meningeal Melanocytoma, Nonmalignant Neoplasm, Recurrent Adult Brain Tumor, Tumors Metastatic to Brain | 09/14 | | | |
NCT02592317: A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer |
|
|
| Recruiting | 1 | 20 | Europe, RoW | JNJ 56021927, Drug Cocktail, Pioglitazone, Rosuvastatin | Aragon Pharmaceuticals, Inc. | Prostatic Neoplasms, Castration-Resistant | 11/16 | 12/24 | | |
ChiCTR2000032539: The human bioequivalence test of Pioglitazone Hydrochloride tablets |
|
|
| Completed | 1 | 64 | | After fasting overnight for at least 10 hours, oral one tablet of the test preparation or reference preparation was taken with 200mL 20% glucose solution on an empty stomach in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administration after ten days. ;After fasting overnight for at least 10 hours, eat a high-fat and high-calorie standard meal 30 minutes before taking 1 test preparation or the reference preparation with 200mL 20% glucose solution in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administra ;After fasting overnight for at least 10 hours, one tablet of the test preparation or reference preparation was taken with 200mL 20% glucose solution on an empty stomach in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administration after ten days ;After fasting overnight for at least 10 hours, eat a high-fat and high-calorie standard meal 30 minutes before taking 1 test preparation or the reference preparation with 200mL 20% glucose solution in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administra | NanJing First Hospital; Jiangsu Deyuan Pharmaceutical Co., Ltd., fully self-financing | Type 2 diabetes | | | | |
ChiCTR2000032538: Study for the bioequivalence of Pioglitazone Hydrochloride and Metformin hydrochloride (15mg/500mg) tablets |
|
|
| Completed | 1 | 59 | | After fasting overnight for at least 10 hours, oral one tablet of the test preparation or reference preparation with 200mL 20% glucose solution on an empty stomach in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administration after ten days ;After fasting overnight for at least 10 hours, eat a high-fat and high-calorie standard meal 30 minutes before taking 1 test preparation or the reference preparation with 200mL 20% glucose solution in the morning of the test day, once every cycle, then subjects were gargled with 40mL water. Cross-administra | Nanjing First Hospital; Jiangsu Deyuan Pharmaceutical Co., Ltd., fully self-financing | Type 2 diabetes | | | | |
NCT02535832: Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA) |
|
|
| Completed | 1 | 16 | US | Pioglitazone, Actos, Placebo | Ohio State University | Rheumatoid Arthritis, Insulin Resistance | 10/22 | 10/22 | | |
NCT04658849: Insulin Resistance Following ADT for Prostate CA |
|
|
| Withdrawn | 1 | 44 | US | Pioglitazone 30 Mg Oral Tablet, Actos, Pioglitazone placebo tablet, Placebo | St. Louis University | Insulin Resistance, Prostate Cancer | 03/23 | 03/23 | | |
NCT03720366: A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients |
|
|
| Completed | 1 | 40 | RoW | enasidenib, CC-90007, AG-221, Arm 1 probes, Arm 2 Probes, Arm 3 probes | Celgene | Leukemia, Myeloid, Acute | 09/23 | 12/23 | | |
NCT05760677: Study on the Efficacy and Safety of Chiglitazar Sodium in PCOS With T2DM |
|
|
| Enrolling by invitation | 1 | 142 | RoW | pioglitazone group: lifestyle intervention+ metformin+ orlistat (obese patients)+ pioglitazone, the Chiglitazar group: lifestyle intervention+ metformin+ orlistat (obese patients)+ Chiglitazar | Affiliated Hospital of Nantong University | PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries, T2D | 09/23 | 09/24 | | |
| Active, not recruiting | 1 | 10 | US | Pioglitazone 30 mg | Johns Hopkins University | Gastroparesis | 09/25 | 10/25 | | |
NCT03866408: Insulin Regulation of Lipolysis and Lipolysis Proteins |
|
|
| Recruiting | 1 | 64 | US | Immediate weight loss, Pioglitazone, Deferred weight loss, Placebo | Mayo Clinic, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Obesity | 12/24 | 12/24 | | |
NCT05960656: SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis |
|
|
| Recruiting | 1 | 169 | US | Empagliflozin 25 MG, Jardiance, Placebo, Placebo for empagliflozin, Pioglitazone 30mg, Actos, Pioglitazone 30mg + Empagliflozin (25 mg), Actos/Jardiance | The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 2 Diabetes, Type 1 Diabetes | 06/27 | 06/27 | | |
NCT05753657: A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer. |
|
|
| Recruiting | 1 | 30 | RoW | Pioglitazone | Rambam Health Care Campus | Metastatic Breast Cancer, Hyperinsulinism, Hyperglycemia Drug Induced | 12/26 | 12/27 | | |
ChiCTR-RNC-12001949: Genetic polymorphisms affect therapeutic efficacy of Pioglitazone in Chinese Patients with type 2 diabetes |
|
|
| Completed | N/A | 100 | | none | The Third Xiangya Hospital, Central South University; The Third Xiangya Hospital, Central South University, self-funded | diabetes | | | | |
ChiCTR-IOR-15006343: The application of new insulin resistance index evaluation of two kinds of drugs for the treatment of PCOS |
|
|
| Not yet recruiting | N/A | 72 | | 500mgTid metformin for 12 weeks, 2 weeks elution and 15mgQd pioglitazone for 12 weeks. ;15mg Qd pioglitazone for 12 weeks, 2 weeks elution and 500mgTid metformin for 12 weeks | Beijing Tsinghua changgeng Hospital; Beijing Tsinghua changgeng Hospital, Merck Serono Diabetes Research Foundation | insulin resistance | | | | |
ChiCTR1800015504: Pioglitazone adjuntive therapy for bipolar depression: the efficacy and potential mechanisms |
|
|
| Recruiting | N/A | 90 | | pioglitazone adjuntive therapy ;blank control | Peking University Sixth Hospital; Peking University Sixth Hospital, the National Natural Science Foundation of China | Bipolar Disorder | | | | |
NCT05422092: Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease |
|
|
| Not yet recruiting | N/A | 80 | NA | Canagliflozin, Canagliflozin tablets, Pioglitazone, Pioglitazone Hydrochloride Tablets | First Affiliated Hospital Xi'an Jiaotong University | Type 2 Diabetes Mellitus With Complication | 01/23 | 12/23 | | |
| Active, not recruiting | N/A | 150 | RoW | Metformin, Glucophage, Gliclazide, Diamicron, Diamicron MR, Sitagliptin, Januvia, Liraglutide, Victoza, Pioglitazone, Actos, Dapagliflozin, Forxiga, Farxiga, human insulin, novorapid, glargine | Weill Cornell Medical College in Qatar, Hamad Medical Corporation, Sidra Medical and Research Center, University of Hull | Diabetes Mellitus Type 2 | 10/23 | 10/24 | | |
| Recruiting | N/A | 60 | US | Pioglitazone, Thiazolidinedione, Placebo | University of Texas Southwestern Medical Center, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Takeda Pharmaceuticals North America, Inc. | Uric Acid Kidney Stone Disease | 11/24 | 12/24 | | |
| Completed | N/A | 201 | US | Brief Behavioral Compliance Enhancement Treatment, BBCET | VA Office of Research and Development | Alcohol Use Disorder | 03/24 | 05/24 | | |
